Shares of Twist Bioscience Corp (TWST) tumbled 7.96% in pre-market trading on Monday, despite reporting a surprise profit for its fiscal third quarter. The sharp decline comes as the company's forward guidance failed to meet analyst expectations, raising concerns about its growth trajectory.

Twist Bioscience reported a net income of $0.33 per diluted share for the quarter ended June 30, a significant turnaround from a loss of $1.47 per share in the same period last year. This result handily beat analyst estimates, which had projected a loss of $0.55 per share. Revenue for the quarter came in at $96.1 million, slightly above the $95.6 million forecast by analysts and up from $81.5 million a year earlier.

However, the company's outlook seems to have spooked investors. Twist Bioscience narrowed its fiscal 2025 revenue guidance to a range of $374 million to $376 million, down from its previous forecast of $372 million to $379 million. This new guidance falls short of the $376.5 million analysts were expecting. Furthermore, for the fourth quarter, the company projects revenue between $96 million and $98 million, below the consensus estimate of $99 million. These projections suggest a potential slowdown in growth, which appears to be the primary driver behind the stock's pre-market plunge.